Annovis Bio (NYSE American: ANVS) is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases. The company has no approved products and generates no commercial revenue, funding operations through equity offerings, warrant exercises, and debt financings. Its sole clinical asset is buntanetap, a small-molecule drug candidate targeting Alzheimer's disease (AD) and Parkinson's disease (PD). As of the 10-K filed March 13, 2026, Annovis had completed a Phase 3 PD Trial (topline efficacy data released July 2, 2024) and was running a Phase 2/3 AD Trial initiated February 2023, with interim analyses built into each study. The company is headquartered in the United States, incorporated in Delaware, and qualifies as a smaller reporting company. Maria Maccecchini serves as President and Chief Executive Officer. Commercial revenue from buntanetap, if any, is not expected for many years pending regulatory approval.

Revenue model

Pre-revenue. Cash needs are met through equity offerings, including common stock, warrants, and pre-funded warrants, as well as proceeds from warrant and stock option exercises. No product sales, licensing fees, or collaboration payments are reported in the FY2025 or FY2024 financial statements included in the filing.

Products and services

Buntanetap: a single small-molecule drug candidate in clinical development for Alzheimer's disease (Phase 2/3 AD Trial initiated February 2023) and Parkinson's disease (Phase 3 PD Trial completed December 4, 2023, topline data released July 2, 2024). No approved or commercialized products as of the filing date.

Customers and end markets

No commercial customers. Target end markets, if buntanetap is approved, are patients with mild to moderate Alzheimer's disease (MMSE score 14 to 24) and early Parkinson's disease (Hoehn and Yahr stages 1, 2, or 3 with OFF times under two hours per day).

Value-chain role

Drug developer with no manufacturing or commercial sales infrastructure. Relies on clinical trial execution and FDA regulatory processes. Consults physicians and healthcare providers, some of whom receive stock or stock options as compensation.

Geographic exposure

United States primary regulatory jurisdiction (FDA). No international commercial operations described in the filing excerpts.

Source: SEC 10-K, filed 2026-03-13

Industry: Pharmaceutical Preparations Peers: Alzamend Neuro Inc Rezolute Inc Atossa Therapeutics Inc Lunai Bioworks Inc INFINITY PHARMACEUTICALS, INC. Puma Biotechnology Inc Inozyme Pharma, Inc. MediciNova Inc